Boehme, Philip, Hansen, Arne, Roubenoff, Ronenn, Scheeren, Joseph, Herrmann, Maximilian, Mondritzki, Thomas, Ehlers, Jan and Truebel, Hubert (2018) How soon will digital endpoints become a cornerstone for future drug development? Drug Discovery Today. ISSN 18785832

Abstract

Digital technologies are transforming healthcare and will provide the basis for more patient-centric innovation in the pharmaceutical industry. Digital endpoints in clinical studies have the potential to drive innovation and reduce costly late-stage failures. This is also currently under consideration by regulatory agencies, such as the US Food and Drug Administration (FDA). The academic–industrial collaboration MOBILISED-D aims to implement and validate real-world walking speed (RWS) as a digital endpoint accepted by regulatory authorities as a first of its class. Previous work has shown that loss of mobility driven by chronic illness and frailty in older patients can be a relevant readout or effect of different diseases and various organ systems.

Item Type:	Article
Date Deposited:	09 Oct 2018 00:45
Last Modified:	09 Oct 2018 00:45
URI:	https://oak.novartis.com/id/eprint/37286